samedan logo
 
 
spacer
home > pmps > summer 2019 > why automate?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Why Automate?

There are many answers to the question 'why automate?', but the bottom line is: if you don’t, you will be left behind. Automation in the pharmaceutical industry affects costs, regulatory compliance, and productivity, so why do we need it?

Data, reproducibility, compliance, and, most importantly, reduction of human error. Can a machine make an error? Of course, it’s called a malfunction. Usually, it is the human who programmed the machine that caused it, so maintenance teams can help provide technical support to make sure the automated process is programmed correctly.

Once the system is set, there are fewer chances for deviation. Automation also provides an opportunity for round-the-clock work because machines do not need to take a break. The benefits of back-up cloud data and encryptions also provide secure systems that can be implemented globally without the need to retrain or reprogram your operations.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

spacer
Randice Altschul
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG ‘Makes it Better’

ACG is consolidating its founding values of caring, collaboration and progressiveness in a comprehensive re-brand. As one of the world's leading suppliers of fully integrated solutions to the global pharmaceutical and nutraceutical industry, ACG is taking this opportunity to share the message at the heart of its operation - ‘Make it Better’
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement